Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

Diabetes Care

Volumn 29, Issue 2, 2006, Pages 254-258

  Bowker, Samantha L ^a,b   Majumdar, Sumit R ^a,b   Veugelers, Paul ^b   Johnson, Jeffrey A ^a,b,c  

^a INSTITUTE OF HEALTH ECONOMICS   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; CHRONIC DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; SCORING SYSTEM; STATISTICAL ANALYSIS; CANADA; COMORBIDITY; COMPARATIVE STUDY; DRUG COMBINATION; HOSPITALIZATION; MIDDLE AGED; MORTALITY; NEOPLASM; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SASKATCHEWAN; SEVERITY OF ILLNESS INDEX; SULFONYLUREA COMPOUNDS;

EID: 33645766204     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/diacare.29.02.06.dc05-1558     Document Type: Article

References (37)

1. Saydah SH, Loria CM, Eberhardt MS, Brancati FL: Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 157:1092-1100, 2003
2. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J: Post-load plasma glucose and cancer mortality in middleaged men and women: 12-year follow-up findings of the Chicago Heart Association Detection Project in Industry. Am J Epidemiol 131:254-262, 1990
3. Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA, Manson JE: Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 26:1752-1758, 2003
4. Weiderpass E, Gridley G, Nyren O, Ekbom A, Persson I, Adami HO: Diabetes mellitus and risk of large bowel cancer. J Natl Cancer Inst 89:660-661, 1997
5. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ: Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160-1167, 2004
6. Maatela J, Aromaa A, Salmi T, Pohja M, Vuento M, Gronroos M: The risk of endometrial cancer in diabetic and hypertensive patients: a nationwide record-linkage study in Finland. Ann Chir Gynaecol Suppl 208:20-24, 1994
7. La Vecchia C, Negri E, Franceschi S, D'Avanzo B, Boyle P: A case-control study of diabetes mellitus and cancer risk. Br J Cancer 70:950-953, 1994
8. Everhart J, Wright D: Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis. JAMA 273:1605-1609, 1995
9. Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, Persson I: Cancer risk in patients with diabetes mellitus. Cancer Causes Control 2:307-314, 1991
10. Balkau B, Barrett-Connor E, Eschwege E, Richard JL, Claude JR, Ducimetiere P: Diabetes and pancreatic carcinoma. Diabetes Metab 19:458-462, 1993
11. Silverman DT, Schiffman M, Everhart J, Goldstein A, Lillemoe KD, Swanson GM, Schwartz AG, Brown LM, Greenberg RS, Schoenberg JB, Pottern LM, Hoover RN, Fraumeni JF Jr: Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 80:1830-1837, 1999
12. Hjalgrim H, Frisch M, Ekbom A, Kyvi KO, Melbye M, Green A: Cancer and diabetes - a follow-up study of two population-based cohorts of diabetic patients. J Intern Med 241:471-475, 1997
13. Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, Speizer FE, Giovannucci E: Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 91:542-547, 1999
14. Will JC, Galuska DA, Vinicor F, Calle EE: Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol 147:816-825, 1998
15. Alexander CM: The coming of age of the metabolic syndrome. Diabetes Care 26:3180-3181, 2003
16. Gapstur SM, Gann PH, Colangelo LA, Barron-Simpson R, Kopp P, Dyer A, Liu K: Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). Cancer Causes Control 12:763-772, 2001
17. Barker BE, Fanger H, Farnes P: Human mammary slices in organ culture. I. Methods of culture and preliminary observations on the effects of insulin. Exp Cell Res 35:437-448, 1964
18. van der Burg BB, Rutteman GR, Blankenstein MA, de Laat SW, van Zoelen EJ: Mitogenic stimulation of human breast cancer cells in a growth-defined medium: synergistic action of insulin and estrogen. J Cell Physiol 134:101-108, 1988
19. Rosenfeld RG: Insulin-like growth factors and the basis of growth. N Engl J Med 349:218-216, 2003
20. Kim YI: Diet, lifestyle, and colorectal cancer: is hyperinsulinemia the missing link? Nutr Rev 56:275-279, 1998
21. Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ: Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 47:111-120, 1998
22. Giovannucci E: Insulin and colon cancer. Cancer Causes Control 6:164-179, 1995
23. Yam D, Fink A, Mashiah A, Ben-Hur E: Hyperinsulinemia in colon, stomach, and breast cancer patients. Cancer Lett 104:129-132, 1996
24. Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding XZ, Adrian TE, Pour PM: Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120:1263-1270, 2001
25. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR, Hardie DG: Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade [article online]. J Biol 2:28, 2003. Available from http://jbiol.com/ content/2/3/28. Accessed 13 December 2005
26. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304-1305, 2005
27. Downey W, Beck P, McNutt M, Stang MR, Osei W, Nichol J: Health Databases in Saskatchewan: Pharmacoepidemiology. 3rd ed. Strom BL, Ed. Chichester, U.K., Wiley, 2000, p. 325-345
28. Johnson JA, Majumdar SR, Simpson SH, Toth EL: Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25:2244-2248, 2002
29. Rawson NS, Robson DL: Concordance on the recording of cancer in the Saskatchewan Cancer Agency Registry, hospital charts and death registrations. Can J Public Health 91:390-393, 2000
30. Von Korff M, Wagner EH, Saunders K: A chronic disease score from automated pharmacy data. J Clin Epidemiol 45:197-203, 1992
31. Bailey CJ, Turner RC. Metformin. N Engl J Med 334:574-579, 1996
32. Defronzo RA, Goodman AM: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: the Multicenter Metformin Study Group. N Engl J Med 333:541-549, 1995
33. Grant PJ: The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 19:64-66, 1996
34. Yang YX, Hennessy S, Lewis JD: Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127:1044-1050, 2004
35. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group. Diabetes Care 21:87-92, 1998
36. Aronow WS: Oral sulfonylureas and CV mortality. Geriatrics 59:45-46, 49, 2004.
37. Mannucci E, Monami M, Masotti G, Marchionni N: All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev 20:44-47, 2004